Table 4. Eligibility for the inclusion criteria of PARADIGM-HF trial.
| PARADIGM-HF criteria | Prevalence | |
|---|---|---|
| Single criteria | ||
| a. Age ≥18 years | 100% | |
| b. LVEF ≤40% | 100% | |
| c. NYHA class II–IV | 80% | |
| d. eGFR ≥30 mL/min/1.73m2 | 89% | |
| e. Serum K+ ≤5.4 mmol/L | 99% | |
| f. SBP, mmHg ≥95 mmHg | 91% | |
| g. Equivalent more than enalapril 10 mg/day | 34% | |
| h. BB treatment | 57% | |
| i. MRA treatment | 53% | |
| Combination criteria | ||
| a + b + c + d | 71% | |
| a + b + c + d + e | 70% | |
| a + b + c + d + e + f | 64% | |
| a + b + c + d + e + f + g | 18% | |
| a + b + c + d + e + f + g′ | 39% | |
| a + b + c + d + e + f + g + h | 12% | |
| a + b + c + d + e + f + g′ + h | 30% | |
| a + b + c + d + e + f + g + h + i | 7% | |
| a + b + c + d + e + f + g′ + h + i | 15% | |
| a + b + c + d + e + f + h + i | 23% | |
| a + b + c + d + e + g′ | 43% | |
Means equivalent more than enalapril 5 mg/day.
BB = beta-blocker; eGFR = estimated glomerular filtration rate; g′ = equivalent more than enalapril 5 mg/day; LVEF = left ventricular ejection fraction; MRA = mineralocorticoid receptor antagonist; NYHA = New York Heart Association; PARADIGM-HF = Prospective Comparison of ARNi with ACE-I to Determine Impact on Global Mortality and Morbidity in Heart Failure; SBP = systolic blood pressure.